India Immunoassay Market By Product (Reagents and Kits, Analyzers/Instruments, Software and Services), By Technology (Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Fluoro Immnoassay (FIA), Chemiluminescence Immunoassay (CLIA), Rapid Test, Others), By Indication (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Diseases, Autoimmune Diseases, Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 2.19 Billion
CAGR (2026-2031)	6.25%
Fastest Growing Segment	Reagents and Kits
Largest Market	West
Market Size (2031)	USD 3.15 Billion

Market Overview

The India Immunoassay Market is expected to grow from USD 2.19 Billion in 2025 to USD 3.15 Billion by 2031 at a 6.25% CAGR. Immunoassay, a biochemical test, precisely measures the presence or concentration of a macromolecule or small molecule in a solution, leveraging the specific binding affinity between an antibody and an antigen to detect analytes of interest. The India immunoassay market is principally driven by the increasing prevalence of chronic and infectious diseases, necessitating accurate and timely diagnosis. Concurrently, advancements in healthcare infrastructure, alongside growing health awareness and demand for rapid diagnostic solutions, including point-of-care testing, further support market expansion. Government initiatives aimed at bolstering diagnostic capabilities and encouraging laboratory automation also contribute significantly to this growth.

According to the India Brand Equity Foundation, India's broader medical devices market was projected to reach US$ 15.2 billion in 2025, reflecting the robust growth within the healthcare sector which encompasses immunoassay diagnostics. Despite this positive trajectory, a significant challenge impeding market expansion is the need to improve accessibility and affordability of these diagnostic tests across diverse demographic and geographic segments in India.

Key Market Drivers

Rising disease burden propels immunoassay demand
The rising burden of chronic and infectious diseases significantly propels the India immunoassay market by creating an urgent demand for accurate and timely diagnostic solutions. Non-communicable diseases, such as cardiovascular ailments and diabetes, are increasing in prevalence, necessitating widespread screening and monitoring. For instance, in 2025, a nationwide survey by the National Statistics Office reported that 25.6% of surveyed individuals experienced cardiovascular ailments, highlighting the substantial need for diagnostic interventions. Immunoassays are essential in detecting these conditions early, allowing for better disease management and improved patient outcomes. This epidemiological shift underscores the critical role of advanced diagnostics.

Technological innovation and strategic investment expand IVD capabilities
Concurrently, technological advancements in immunoassay platforms are a pivotal driver, transforming diagnostic capabilities across India. Innovations are leading to the development of more sensitive, specific, and rapid testing methods, including automated systems and point-of-care solutions. These advancements enhance laboratory efficiency and extend diagnostic reach, particularly in underserved regions. A notable example is the financial assistance provided by the Technology Development Board in March 2026 to Chennai-based Acrannolife Genomics for an advanced manufacturing facility supporting its Trunome GrafAssure and TBFYND IVD kits. This focus on innovation is integral to the broader in-vitro diagnostics sector. According to the Association of Diagnostics Manufacturers of India (ADMI), in FY2025–26, the in-vitro diagnostics (IVD) segment was valued at approximately $5.60 billion, underscoring the market's substantial size and the impact of technological evolution.

Download Free Sample Report

Key Market Challenges

Access and Affordability Barriers
A significant challenge impeding the expansion of the India Immunoassay Market is the need to improve accessibility and affordability of these diagnostic tests across diverse demographic and geographic segments. The high cost associated with immunoassay testing and the limited financial capacity of a large segment of the Indian population directly hinder market growth. This issue is particularly pronounced in rural and lower-income areas, where economic constraints often lead to delayed or foregone essential diagnostic procedures.

High Out-of-Pocket Costs and Uneven Diagnostic Access
The substantial out-of-pocket expenditure for healthcare services acts as a primary deterrent. According to NATHEALTH, in 2026, approximately 44% of health expenditure in India was covered directly by patients, with over 400 million individuals still lacking effective health insurance coverage. This reliance on personal funds makes advanced immunoassay tests financially inaccessible for many, thereby suppressing demand and limiting the volume of tests performed. Additionally, the uneven distribution of diagnostic centers and trained personnel, especially outside major urban hubs, restricts the physical availability of these tests, further hampering market penetration and overall growth potential across the country.

Key Market Trends

AI and ML-Driven Immunoassay Analytics Improve Diagnostic Precision
Leveraging Artificial Intelligence and Machine Learning in immunoassay analysis is a significant trend, enhancing diagnostic precision and efficiency. These computational methods enable rapid processing of complex immunoassay data, improving disease prognostication and personalized treatment. AI algorithms detect subtle biomarker patterns, leading to earlier, more accurate diagnoses. This integration streamlines laboratory workflows, reducing turnaround times and minimizing human error. According to the India insights of Deloitte's State of AI in the Enterprise report for 2026, 40 percent of Indian respondents report significant or full usage of AI, compared with a global average of approximately 28 percent. This widespread adoption signals increasing application within specialized diagnostic fields like immunoassay.

Consolidation of Diagnostic Networks Through Strategic Acquisitions
The consolidation and expansion of diagnostic chain networks represent another significant trend, fueled by demand for standardized, accessible, and high-quality testing across diverse regions. Major diagnostic chains are actively acquiring smaller, independent laboratories and establishing new collection centers, particularly in Tier-2 and Tier-3 cities. This strategy enhances market penetration and standardizes testing protocols, increasing reliability. Illustrating this trend, Redcliffe Labs acquired Pune-based Megavision Diagnostics Centre for approximately Rs 40 crore, as reported by Indian Startup Times in August 2026. Such strategic acquisitions are crucial for integrating the fragmented Indian diagnostic landscape into a more organized and expansive market structure.

Segmental Insights

Growth Drivers for Reagents and Kits in India's Immunoassay Market
The Reagents and Kits segment is experiencing rapid growth within the India Immunoassay Market, primarily driven by the increasing demand for precise and efficient diagnostic testing. This surge is fueled by the rising prevalence of chronic and infectious diseases across the country, necessitating frequent and accurate immunoassay examinations. Furthermore, the continuous expansion of diagnostic infrastructure, including laboratories and testing centers, particularly in semi-urban and rural regions, significantly boosts the recurring consumption of these essential consumables. The adoption of advanced automated immunoassay platforms also contributes to this growth, as these systems rely heavily on a steady supply of specific reagents and kits for their operation, underscoring their critical role in the evolving diagnostic landscape.

Regional Insights

West Dominates India Immunoassay Market Through Advanced Healthcare Infrastructure
The West significantly leads the India Immunoassay Market, primarily driven by its rapidly advancing healthcare infrastructure and a substantial presence of sophisticated diagnostic facilities. This region, encompassing major urban centers, benefits from a robust ecosystem that attracts considerable private laboratory investments and fosters collaborations between leading pharmaceutical companies and esteemed research institutions. The availability of state-of-the-art diagnostic capabilities ensures accurate and timely disease detection, further fueling the demand for immunoassay technologies. This proactive approach to healthcare, coupled with a dense urban population, firmly establishes the West's dominant position in the market.

Recent Developments

• In December 2025, Destina Genomica launched its specialized LiverAce™ Research Use Only (RUO) kits globally, with a significant introduction into the Indian market. These immunoassay kits were designed to offer high-specificity detection of liver injury biomarkers, catering to pharmaceutical and preclinical research needs. The availability of these advanced immunoassay tools in India supported the growing demand for precise diagnostic solutions in liver health research and development. This product launch represented an important step in enhancing research capabilities within the Indian immunoassay landscape for disease biomarker discovery.
• In September 2025, Abbott introduced enhanced immunoassay technologies for its diagnostic platforms, aiming to deliver faster and more reliable testing capabilities. These advancements were designed to support a broad spectrum of clinical applications, including infectious diseases and cardiology. The introduction of these improved immunoassay solutions by Abbott was critical for strengthening diagnostic accuracy and efficiency in the Indian healthcare system. This move underscored the company's continuous efforts to provide advanced diagnostic tools that address key health challenges and improve patient outcomes within the India Immunoassay Market.
• In March 2024, Fapon, a global life sciences company, introduced a range of novel in-vitro diagnostic (IVD) products, technologies, and solutions specifically for the Indian market at Medical Fair India. These introductions included new biomarkers, blockers, bulk reagents, various assays, and advanced instrument platforms. The offerings were designed to meet the evolving requirements of the local healthcare industry, empowering Indian IVD manufacturers. This initiative by Fapon demonstrated a commitment to supporting local partners by providing comprehensive, one-stop solutions to foster the development of the Indian in-vitro diagnostics sector, which significantly encompasses immunoassay technologies.
• In January 2024, Fujirebio Holdings and Agappe Diagnostics announced a Contract Development and Manufacturing Organization (CDMO) partnership. This collaboration aimed to facilitate the local production of CLIA-based immunoassay reagents specifically for Agappe Diagnostics' Mispa i60 and i121 platforms in India. This strategic alliance enabled Agappe Diagnostics to enhance its offerings with comprehensive, locally manufactured chemiluminescence solutions within the Indian market. This development was crucial for advancing in-country diagnostic capabilities, directly supporting the expansion and accessibility of advanced immunoassay testing solutions for healthcare providers across India.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Abbott India Ltd.
• BioMérieux India Pvt. Ltd.
• Bio-Rad laboratories India Pvt.Ltd
• Becton Dickinson Pvt.Ltd
• Thermo Fisher Scientific India Pvt. Ltd.
• Danaher India (DHR Holding India Pvt. Ltd.)
• Siemens Healthcare Private Limited
• Randox Laboratories (India) Pvt. Ltd.
• Sysmex India Pvt. Ltd.

By Product	By Technology	By Indication	By End User	By Region
Reagents and Kits Analyzers/Instruments Software and Services	Radioimmunoassay (RIA) Enzyme Immunoassays (EIA) Fluoro Immnoassay (FIA) Chemiluminescence Immunoassay (CLIA) Rapid Test Others	Therapeutic Drug Monitoring Oncology Cardiology Endocrinology Infectious Diseases Autoimmune Diseases Others	Hospitals & Clinics Pharmaceutical & Biotechnology Companies Academic & Research Institutions Others	North India East India West India South India

Report Scope:

In this report, the India Immunoassay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Immunoassay Market, By Product:

• Reagents and Kits
• Analyzers/Instruments
• Software and Services

• India Immunoassay Market, By Technology:

• Radioimmunoassay (RIA)
• Enzyme Immunoassays (EIA)
• Fluoro Immnoassay (FIA)
• Chemiluminescence Immunoassay (CLIA)
• Rapid Test
• Others

• India Immunoassay Market, By Indication:

• Therapeutic Drug Monitoring
• Oncology
• Cardiology
• Endocrinology
• Infectious Diseases
• Autoimmune Diseases
• Others

• India Immunoassay Market, By End User:

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• Others

• India Immunoassay Market, By Region:

• North India
• East India
• West India
• South India